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Introduction
Plasminogen activator inhibitor Type 2 (PAI-2) was isolated 45 
years ago as a human placental-derived inhibitor of  urokinase 
plasminogen activator (uPA) [1]. The biological and clinical prop-
erties of  PAI-2 have been extensively studied [2] and recognized 
to be important in fibrinolysis, wound healing and tissue remode-
ling. Nevertheless, the role of  PAI-2 as a serine protease inhibitor 
(serpin) remains enigmatic with a variety of  intracellular functions 
attributed to PAI-2, including its ability to influence apoptosis, cell 
differentiation, and immune response [3, 4].
In the absence of  disease, wounding or surgery, plasma levels of  
PAI-2 are undetectable except during pregnancy when its pres-
ence in plasma is largely due to PAI-2 secretion by the trophoblast 
cells of  the placenta [5]. The concentration of  PAI-2 in plasma 
increases with gestational age until term and then returns to unde-
tectable levels within six weeks after delivery [6, 7]. Independent 
of  pregnancy, secreted or released PAI-2 has been identified in 
various biological fluids, including human tears [8], gingival fluid 
[9] and saliva [10].
Myopia has been becoming more prevalent worldwide [11, 12], es-
pecially in younger individuals and Asian populations in particular 
[13, 14]. Laser in situ keratomileusis (LASEK) and excimer laser 
photorefractive keratectomy (PRK) is often chosen to ameliorate 
myopia. Therefore corneal wound healing and the concomitant 
changes in tear enzymes that affect wound healing become im-
portant processes.
Women who became pregnant after LASEK have experienced 
changes in visual acuity and spherical equivalent [15]. Refractive 
regression and corneal haze have been reported in eyes of  women 
who became pregnant after PRK for the treatment of  myopia 
[16]. In rabbits, pregnancy has been identified as a risk factor for 
the development of  corneal haze after PRK [17]. In addition, cor-
neal thickness, curvature, and sensitivity as well as tear composi-
tion and refraction can all change during pregnancy [18, 19].
Pregnant women have been found to experience more gingivitis 
than non-pregnant women [20, 21]. Previous studies assessed the 
influence of  pregnancy on the concentration of  PAI-2 found in 
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gingival crevicular fluid (GCF) [9, 22]. During pregnancy, levels 
of  estradiol (E2) and progesterone (P4) rise with gestational age. 
E2 and P4 have been shown to have an inhibitory effect on PAI-
2 production in monocytes [23]. Pregnancy-related hormonal 
changes and levels of  PAI-2 in gingival crevicular fluid (GCF) 
are thought to be responsible for aggravated gingival inflamma-
tory symptoms during pregnancy [20, 21]. Sex hormone changes 
during different phases of  the menstrual cycle have effects on 
gingival tissues and PAI-2 levels in GCF [24].
Two types of  plasminogen activators exist: uPA and tissue-type 
plasminogen activator (tPA). The plasminogen activator cascade 
is controlled at different levels, one of  which is the inhibition of  
plasminogen activator activity (PAA) by plasminogen activator in-
hibitors (PAIs). In addition to PAI-2, another PAI is plasminogen 
activator inhibitor Type 1 (PAI-1), which is produced by vascular 
smooth muscle cells, platelets and hepatocytes. 
In the eye, uPA is a normal component of  tear fluid, originating 
from conjunctival vessels and corneal epithelial cells [25]. Values 
of  PAI-2 measured in tear samples (non-pregnancy) have been 
reported [8] and play a role in inhibition of  uPA [26]. Levels of  
tPA and PAI-1 were below the detection limit of  4 ng/ml of  the 
enzyme-linked immunosorbent assay (ELISA) test in normal 
(non-pregnancy) human tears [8].
Here, we have measured levels of  PAIs in the tears of  pregnant 
women at different gestational times and postnatal to determine 
if  those levels are affected by pregnancy. It should be noted that 
changes in levels of  PAIs in tears during pregnancy have not been 
examined previously. In addition, we measure E2, P4, PAI-1 and 
PAI-2 in blood of  pregnant women.
Materials and Methods
Study Subjects
Participants were selected for these studies after obtaining in-
formed consent in adherence to the Declaration of  Helsinki since 
the study protocol has been approved by the institute's committee 
on human research. The study subjects were under survey during 
pregnancy at the University of  Debrecen, Department of  Obstet-
rics and Gynecology.
In this study, both tear and blood samples were collected oppor-
tunistically from pregnant women during pregnancy and within 1 
week after delivery. The ages of  pregnant women were between 
19-33 years, with a mean (SD) age of  27.42 (4.13) years. These 
were all full term (39-40 weeks, one at 37 weeks), normal pregnan-
cies, without pre- or postnatal difficulties. None of  the subjects 
had a history of  hemostatic disorders or other relevant diseases. 
None were taking any medications. Two pregnant women were 
wearing contact lenses during pregnancy.
Sample Collection
Tear samples were collected from the participants’ eyes at the out-
patient clinic of  the University of  Debrecen Obstetrics and Gy-
necology Department. Samples consisted of  tears collected with 
glass capillaries [27] from the lower tear meniscus (a horizontal 
thickening of  the precorneal tear film by the lower margin) at 
the lateral canthus. We were careful not to touch the conjunc-
tiva. Corneal injury or incision did not occur. We used the same, 
standardized collection method throughout the study. The dura-
tion of  the sampling time was recorded and the secretion rate 
was calculated in µl/min (5-18 µl/min). Samples were centrifuged 
(1800 rpm) for 8-10 minutes right after collection and superna-
tants were deep-frozen at -80°C and were thawed only once for 
measurements.
For some participants, samples were obtained at successive obstet-
ric visits. Where the volume of  tear sample was sufficient, a du-
plicate determination was made and the results averaged to form 
a “measurement.” Tear sample determinations from 19 pregnant 
women yielded 56 measurements of  tear PAI-2. Tear sample de-
terminations from 13 pregnant women yielded 45 measurements 
of  tear PAI-1.
Blood samples, 4 ml from the ulnar vein, were drawn, collected in 
tubes containing 0.5 ml 0.105 M Trisodium Citrate as anticoagu-
lant, and put on ice. After centrifugation (1800 rpm, 10 minutes), 
plasma aliquots were tested for PAI-2, PAI-1, E2 and P4. Blood 
sample determinations from 25 pregnant women yielded 87 meas-
urements of  blood PAI-2 and from 10 pregnant women yielded 
20 measurements of  blood PAI-1. Blood sample determinations 
from 17 women yielded 51 measurements of  blood E2 and P4.
Measurement of  PAI-2 and PAI-1
ELISA tests (Imubind ELISA, American Diagnostica GmbH. 
Pfungstadt, Germany) were used to analyze the tear and blood 
samples for PAI-2 and PAI-1based on the manufacturer’s instruc-
tions. The lower detection limit was 100 pg/ml for PAI-2 and 4 
ng/ml for PAI-1. Free PAI-2 and PAI-2 complexes, as well as free 
PAI-1 and PAI-1 complexes, are recognized with equal sensitivity.
For comparison purposes, we also report age-matched measure-
ments of  PAI-2 and PAI-1 in tears taken from non-pregnant 
women who participated in a previous study [8] conducted at the 
University of  Debrecen Ophthalmology Department. For non-
pregnant tear controls, tear samples from 17 non-pregnant wom-
en produced 17 tear PAI-2 measurements and tear samples from 
5 non-pregnant women yielded 12 tear PAI-1 measurements.
Measurement of  E2 and P4
E2 and P4 from blood samples were analyzed according to the 
manufacturer’s instructions using chemiluminescence immunoas-
says (Elecsys Estradiol CalSet II and Elecsys Progesterone II Cal-
Set, Roche Diagnostics GmbH, Mannheim, Germany).
Statistical methods
Standard statistical procedures were used to compare measure-
ments between different time periods using t-tests for means with 
equal variances. Differences resulting in P < 0.05 were considered 
statistically significant. In addition, repeated measurement analy-
sis of  variance was used to assess the variation of  PAI-2 levels 
within and between individuals over the gestation periods.
Results and Discussion
Figure 1 shows the measured mean values of  PAI-2 in tears of  
pregnant women. The differences between mean values are not 
statistically significant for the different time periods of  measure-
ment. Hence, the trend line is essentially flat. The non-pregnant 
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mean value (SD) of  measurements taken from our previous study 
was 26.7 (20.5) and the differences between it and each of  the 
values represented in Figure 1 were not statistically significant.
Figure 2 presents mean values of  PAI-2 from blood samples of  
pregnant women. Here the difference between week 10.7 mean 
values and week 41(post-partum) mean value is not statistically 
significant. However, there is a steep rise in the mean value of  the 
PAI-2 seen at week 16.1, week 24.2, and week 34.9, with statisti-
cally significant differences between each of  these and week 10.7 
and week 41 mean values. This is represented by a rising quadratic 
trend.
Repeated measurement analysis of  variance was performed on 
the PAI-2 measurements. For PAI-2 levels in tears, the variance 
of  measurements taken from different participants was 4.95 times 
greater than the variance within the individual participant’s meas-
urements over the five gestation periods. This represents a statisti-
cally significant difference, p < 0.01, between the measurements 
taken from different participants. For PAI-2 levels in blood, the 
variance ratio was 1.06 for the variance within an individual par-
ticipant’s measurements over the five gestation periods versus be-
tween participants. Here there was not a statistically significant 
difference, p = 0.41, between the measurements taken from dif-
ferent participants.
Considering the variance of  measurements between gestation pe-
riods versus the variance from measurements from all participants 
at each of  the five gestation periods, the variance ratio was 1.66 
for PAI-2 in tears representing no statistically significant differ-
ence, p = 0.30, between measurements taken at the different ges-
tation periods. For PAI-2 in blood, the variance ratio was 1493.43 
representing a statistically significant difference, p < 0.001, be-
tween the measurements taken at different gestation periods.
All of  the tear PAI-1 measurements, across the span of  gestation, 
postnatal and non-pregnant subjects (20 pregnant and 12 non-
pregnant measurements) were below the 4 ng/ml detection limit 
of  the ELISA kit. Therefore, due to the limit of  sensitivity of  
our testing regime, PAI-1 levels were not seen to be significantly 
increased in tears due to pregnancy. A more sensitive test will be 
required to further investigate this situation [28]. The blood PAI-
1 measurements yielded mean values (SD) of  85.8 (29.0), 90.5 
(32.2) and 125.9 (26.1) ng/ml at 11, 16 and 24 weeks gestation. 
Since PAI-1 was not at detectable levels in tears, this cannot be a 
basis for tear-blood comparison of  PAI-1 levels. 
Figures 3 and 4 present mean values of  E2 and P4, respectively, 
from blood samples of  pregnant women. In both figures, there is 
a steep rise in mean values with gestation.
Normal pregnancies are associated with major changes in all as-
pects of  hemostasis [29, 30]. Thrombosis is rare in the first tri-
mester but coagulation due to a decrease of  fibrinolytic activity 
is enhanced during pregnancy, especially in the second and third 
trimester. Thus normal pregnancy presents as a hypercoagulable 
state. This condition protects pregnant women from fatal hem-
orrhage during delivery, but predisposes them to thromboembo-
lism. The coagulation activity is balanced despite large changes 
in blood levels of  tPA, uPA, PAI-1 and PAI-2 [31, 32] in normal 
pregnancy. This balance and change are needed to make uterine 
artery and umbilical artery hemodynamics more baby-friendly (i.e. 
high flow, low resistance) with increasing gestational age and to 
ensure that the delivery is not fatal for the mother. The proteo-
lytic activity of  the human body, including this function of  PAI 
in tears, is under sensitive control and serious complications may 
occur if  this system is disturbed.
One observation from our study (Figure 1) is that PAI-2 levels in 
tears of  pregnant women are not higher than the levels found in 
non-pregnant women and are not correlated with gestational age 
(R2 = 0.050). Another observation (Figure 2) is that PAI-2 levels 
in blood showed a continuous increase through the duration of  
pregnancy, with a quadratic trend with respect to gestation age (R2 
= 0.997). The analysis of  variance results give further validation 
to these observations by showing that the error bars in Figure 1 
do not hide a potential rhythmic trend of  PAI-2 in tears in each 
woman.
The PAI-2 levels in blood, rising with gestational age, are signifi-
cantly higher than the mean PAI-2 values measured in tears. Thus 
the PAI-2 levels in tears are not correlated with blood PAI-2 levels 
and not driven by the increased systemic levels of  PAI-2 in the 
blood stream. Also, although the E2 and P4 values increase with 
gestation (Figures 3 and 4), the tear PAI-2 values are not corre-
lated with these hormone levels. These results suggest that PAI-2 
levels in tears and PAI-2 regulated proteolysis at the ocular surface 
are under local control.
Although pregnancy is a risk factor for the development of  cor-
 Figure 1. PAI-2 in Tears of  Pregnant Women.
PAI-2 levels in tear samples during pregnancy. The vertical error bars represent one standard deviation from the mean PAI-2 concen-
tration. The horizontal error bars represent one standard deviation from the mean gestation time in weeks. The trend line is y = -0.11 x 
+ 27.9, with R2= 0.050.
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neal haze after PRK [17], our measurements on tears of  pregnant 
women indicate that tear PAI-2 is not elevated during pregnancy 
in the absence of  wounding or surgery. However, if  the ocular 
surface is wounded or undergoes surgery, local PAI-2 elevating 
mechanisms could be more effective during pregnancy than in the 
absence of  pregnancy, especially if  these local mechanisms were 
stimulated by increased systemic PAI-2 levels during pregnancy. 
In pathological conditions, after wounding or following surgery, 
the permeability of  conjunctival blood vessels generally grows, 
thereby pro-enzyme forms of  proteases and protease inhibitors 
may appear in tears via transudation [33]. In addition to tear spe-
cific proteins, serum proteins, such as albumin, transferrin and 
IgG, can also be present in tears [34]. Furthermore, increases of  
PAI levels in tears may occur due to release from complexes in the 
tear fluid or from damaged epithelial cells at the ocular surface. 
Conjunctival epithelial cells and systemic hormone levels can also 
affect corneal conditions [35]. These are local mechanisms that 
could raise the levels of  PAIs in tears as a response to pathological 
conditions and cause incomplete wound healing.
 Figure 2. PAI-2 in Blood of  Pregnant Women.
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 Figure 3. E2 in Blood of  Pregnant Women.
PAI-2 levels in blood samples during pregnancy. The vertical error bars represent one standard deviation from the mean PAI-2 concen-
tration. The horizontal error bars represent one standard deviation from the mean gestation time in weeks. The trend during gestation 
is y = 0.12 x2 + 0.87 x, with R2= 0.997.
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E2 levels in blood samples during pregnancy. The vertical error bars represent one standard deviation from the mean PAI-2 concen-
tration. The horizontal error bars represent one standard deviation from the mean gestation time in weeks. The trend is y = 0.01 x2 + 
0.33 x, with R2= 0.971.
 Figure 4. P4 in Blood of  Pregnant Women.
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P4 levels in blood samples during pregnancy. The vertical error bars represent one standard deviation from the mean PAI-2 concentra-
tion. The horizontal error bars represent one standard deviation from the mean gestation time in weeks. The trend is y = 0.26 x2 – 0.74 
x, with R2= 0.989.
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The common carotid artery separates into internal and external 
carotid arteries as it supplies blood to the head and neck. The 
ophthalmic artery is a branch of  the internal carotid and supplies 
blood to the brain and eyes. The maxillary artery is a branch of  
the external carotid and supplies the cheek mucosa, teeth, gin-
givae, and palate. The degree of  systemic influence or isolation 
from the biochemical constituents in the carotid blood stream 
could differ in the eye (tear constituents) and mouth (GCF con-
stituents) depending on differences in the properties of  the in-
ternal and external carotid systems. The independence of  PAI-2 
levels in tears and GCF from the progression of  pregnancy might 
indicate the possibility of  tight junction barriers to the elevated 
systemic blood composition levels.
In general, performing surgery on pregnant women is not rec-
ommended [36]. For refractive surgery, waiting three months is 
suggested after giving birth and/or breastfeeding because of  hor-
monal changes that can affect the refractive error and possibly 
induce effects on corneal wound healing. However in some cases, 
pregnant women undergo corneal surgeries, typically because of  
traumatic causes or when pregnancy was not identified in its early 
stage [15, 16].
Some knowledge of  the enzymatic changes during pregnancy 
might help to improve our understanding [37, 38]. Further re-
search into this complex system is necessary so that ophthalmic 
interventions and surgeries, which may become necessary during 
pregnancy, can be performed with greater safety and with reduced 
risk of  postoperative complications.
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